» Articles » PMID: 26846485

Pharmacokinetics of Saquinavir Mesylate from Oral Self-Emulsifying Lipid-Based Delivery Systems

Overview
Date 2016 Feb 6
PMID 26846485
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Although lipid-based drug delivery systems have gained much importance in recent years due to their ability to improve the solubility and bioavailability of poorly soluble drugs, compartmental pharmacokinetic analyses have not been extensively explored. The oral pharmacokinetics of commercial liquid formulation and a developed semisolid system containing saquinavir mesylate (SQVM) were compared in Beagle dogs. A compartmental analysis after intravenous bolus administration of this drug (1 mg/kg) was also performed.

Method: Pharmacokinetic profiles were analyzed using both non-compartmental and compartmental approaches. Plasma concentration of the drug was determined by high-performance liquid chromatography/tandem mass spectrometry (LC/MS/MS).

Results: The disposition curve of SQVM given intravenously was better described by a three-compartment model. In contrast, plasma profiles obtained following the oral administration were fitted to a two-compartment model with lag time due to the fact that the distribution phase was masked by the absorption phase in these formulations.

Conclusion: The proposed semisolid lipid system was found to be a promising formulation for commercial purposes given the similarity of SQVM absorption rate to that from the commercial liquid formulation.

Citing Articles

Overcoming Solubility Challenges: Self-emulsifying Systems for Enhancing the Delivery of Poorly Water-Soluble Antiviral Drugs.

Kapoor D, Sharma D, Gaur M, Prajapati B, Limmatvapirat S, Sriamornsak P Pharm Nanotechnol. 2024; 13(1):117-132.

PMID: 38192138 DOI: 10.2174/0122117385280541231130055458.


Development Of Saquinavir Mesylate Nanoemulsion-Loaded Transdermal Films: Two-Step Optimization Of Permeation Parameters, Characterization, And Ex Vivo And In Vivo Evaluation.

Hosny K Int J Nanomedicine. 2019; 14:8589-8601.

PMID: 31802871 PMC: 6830379. DOI: 10.2147/IJN.S230747.

References
1.
Neervannan S . Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol. 2006; 2(5):715-31. DOI: 10.1517/17425255.2.5.715. View

2.
Guiard-Schmid J, Poirier J, Meynard J, Bonnard P, Gbadoe A, Amiel C . High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother. 2003; 47(3):986-90. PMC: 149294. DOI: 10.1128/AAC.47.3.986-990.2003. View

3.
Staats D, Fisher J, Connolly R . Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. Drug Metab Dispos. 1991; 19(1):144-8. View

4.
Caon T, Konig R, da Cruz A, Goncalves Cardoso S, Campos C, Cuffini S . Development and physicochemical characterization of saquinavir mesylate solid dispersions using Gelucire 44/14 or PEG 4000 as carrier. Arch Pharm Res. 2013; 36(9):1113-25. DOI: 10.1007/s12272-013-0142-2. View

5.
Lunn D, Aarons L . The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J Pharmacokinet Biopharm. 1998; 26(1):47-74. DOI: 10.1023/a:1023224824228. View